# Amprius Technologies

Type: Company (AMPX)

Source: GetYourBrief — https://getyourbrief.com/entity/amprius-technologies
Canonical HTML page: https://getyourbrief.com/entity/amprius-technologies

## Timeline

- **2026-03-04**: FY 2025 Earnings — Released full-year financial results and updated 2026 clinical guidance.
- **2026-03-04**: FY 2025 Earnings — Official reporting of full-year financial results and 2026 clinical guidance.
- **2026-03-04**: FY2025 Earnings — Released full-year results highlighting commercial scaling and Colorado facility progress.
- **2026**: Anticipated Data — Expected top-line data readouts for multiple Phase 2 programs.
- **2026**: Cibotercept Data — Anticipated top-line data from the Phase 2 TROPOS trial in PAH patients.
- **2026 (projected)**: Brighton Fab Launch — Expected commencement of high-volume manufacturing in Colorado.
- **2025-Q3**: Cibotercept Progress — Initiated additional cohorts in PAH studies to evaluate dose-response.
- **2025-Q3**: KER-050 Expansion — Initiation of the global Phase 2/3 trial for elritercept in lower-risk MDS.
- **2025-Q3**: 500 Wh/kg Milestone — Verified performance of 500 Wh/kg cells with key aerospace partners.
- **2025-Q1**: Trial Expansion — Keros expanded the TROPOS trial to include broader MDS patient populations.
- **2025-Q1**: Capital Infusion — Keros raised $140 million in a follow-on offering to fund late-stage TGF-beta trials.
- **2025-Q1**: Capacity Expansion — Amprius increased production capacity at its Fremont pilot line to meet initial eVTOL demand.

## Recent coverage (6 stories, network-wide)

### Sustainable Infrastructure and Next-Gen Energy Drive 2025 Industrial Growth
2026-03-06 00:21:18 · Sector: climate · Sentiment: Positive · Impact: 6/10 · Sources: 8

Industrial leaders in sustainable packaging and advanced energy reported robust Q4 2025 results, driven by a surge in data center power demand and high-density battery technology. The convergence of automation and NDAA-compliant energy storage is signaling a significant maturation of the green industrial economy.
Full story: https://getclimatebrief.com/story/sustainable-infrastructure-energy-trends-2025

### Automation and Resilient Sourcing Drive Logistics Sector Recovery
2026-03-06 00:13:36 · Sector: supply · Sentiment: Positive · Impact: 6/10 · Sources: 8

Industrial and logistics providers are pivoting toward high-margin automation and domestic-compliant sourcing to navigate a bifurcated global economy. While North American demand for automated packaging and specialized power solutions remains robust, regulatory constraints and regional weakness in Europe continue to challenge traditional shipping and bunkering segments.
Full story: https://getsupplybrief.com/story/logistics-automation-sourcing-trends-q4-2025

### Defense-Tech Pivot: Amprius Hits NDAA Milestones as Aerospace Demand Surges
2026-03-06 00:13:02 · Sector: space · Sentiment: Positive · Impact: 6/10 · Sources: 8

Amprius Technologies has achieved full NDAA compliance for its silicon anode battery supply chain while expanding its Defense Innovation Unit contract to $14.8 million. Concurrently, Stabilis Solutions reported a 17% surge in aerospace revenue, driven by heightened commercial launch activity and a strategic shift toward defense-adjacent infrastructure.
Full story: https://getspacebrief.com/story/amprius-ndaa-compliance-stabilis-aerospace-growth

### Amprius Technologies FY2025: Silicon Anode Scaling and Aviation Decarbonization
2026-03-04 23:38:39 · Sector: climate · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Amprius Technologies reported its full-year 2025 financial results, highlighting a critical transition from pilot-scale production to industrial commercialization of its high-energy silicon anode batteries. The company is positioning its ultra-high-density storage solutions as the primary enabler for the burgeoning eVTOL and defense aviation sectors.
Full story: https://getclimatebrief.com/story/amprius-technologies-fy2025-earnings-analysis

### Keros Therapeutics Strengthens TGF-β Pipeline as 2025 Financials Signal Growth
2026-03-04 23:38:04 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Keros Therapeutics reported robust fourth-quarter and full-year 2025 financial results, highlighting significant clinical progress across its TGF-β superfamily pipeline. The company remains well-capitalized to advance its lead assets, elritercept and cibotercept, through critical Phase 2 and Phase 3 milestones in 2026.
Full story: https://getbiobrief.com/story/keros-therapeutics-q4-2025-financial-results-analysis

### Keros Therapeutics Advances TGF-β Pipeline Amid Q4 2025 Financial Results
2026-03-04 23:37:29 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Keros Therapeutics reported its full-year 2025 results, highlighting significant clinical progress in its TGF-β protein superfamily pipeline for hematologic and cardiovascular disorders. The company maintains a robust cash position to fund pivotal trials for elritercept and cibotercept through key upcoming data readouts in 2026.
Full story: https://gethealthbrief.com/story/keros-therapeutics-q4-2025-financial-results-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.